NCT03683745

Brief Summary

Appropriate targeting of interventions for neglected tropical diseases (NTDs) that require innovative and intensified disease management (IDM) requires accurate data on the distribution of these diseases within endemic countries. In most instances however, existing case register data generated through national health management information systems or during programmatic activities do not provide an accurate representation of the true burden of IDM NTDs. This study will pilot a cluster randomized screening and confirmation survey to estimate the burden of IDM NTDs characterised by skin conditions associated with long-term disfigurement and disability. These include: leprosy, Buruli ulcer, yaws and lymphoedema and hydrocele resulting from lymphatic filariasis. The survey is being conducted in one county in Liberia. The protocol involves community-level screening by community health volunteers trained to use photo-based visual aids to recognise changes in the skin that broadly indicates patent infection. All suspected cases will be verified in their homes by local and national experts trained in the diagnosis of skin-presenting NTDs. The survey will generate accurate district-level prevalence estimates of leprosy, yaws, Buruli ulcer and lymphatic filariasis-associated lymphoedema and hydrocele and quantify the total costs and cost per case detected. In addition, results from this protocol will be compared with routinely collected case register data, to better understand how health system records reflect the true disease situation on the ground and quantify unmet need.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
56,285

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Jun 2018

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

June 14, 2018

Completed
3 months until next milestone

First Submitted

Initial submission to the registry

September 19, 2018

Completed
6 days until next milestone

First Posted

Study publicly available on registry

September 25, 2018

Completed
1 month until next milestone

Primary Completion

Last participant's last visit for primary outcome

October 30, 2018

Completed
2 months until next milestone

Study Completion

Last participant's last visit for all outcomes

December 30, 2018

Completed
Last Updated

June 10, 2024

Status Verified

June 1, 2024

Enrollment Period

5 months

First QC Date

September 19, 2018

Last Update Submit

June 7, 2024

Conditions

Keywords

disease burden

Outcome Measures

Primary Outcomes (3)

  • Population prevalence of Lymphatic Filariasis

    Clinical signs of lymphoedema and hydrocele associated with lymphatic filariasis

    Over a four month period

  • Population prevalence of Yaws

    Clinical signs and PCR-confirmed yaws

    Over a four month period

  • Population prevalence of Buruli Ulcer

    Clinical signs and PCR-confirmed Buruli ulcer

    Over a four month period

Secondary Outcomes (3)

  • Population prevalence of leprosy

    Over a four month period

  • Population prevalence of BU and yaws in children

    Over a four month period

  • Population prevalence of category 3 Buruli Ulcer

    Over a four month period

Study Arms (1)

Maryland

Maryland is a county in southeast Liberia. Survey clusters based on catchment populations served by community health volunteers (CHVs) around 24 district health facilities (primary sampling unit). Clusters will constitute \~600 people (\~100 households) with population-weighted cluster selection applied. In total, 80 clusters will be required. CHVs would conduct house-to-house visits to develop a full census and listing of all possible cases using broad case definitions. Full details of all potential cases will then be passed to an expert verification team based at the closest health facility. Suspected cases will arrive at the health facility over a 10-day verification period to receive a diagnosis using clinical examination and/or laboratory confirmation.

Eligibility Criteria

Sexall
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

All individuals resident in the study clusters, which were selected with probability proportional to size.

You may qualify if:

  • Adults over 18 must be willing and able to give informed consent for examination, and children over 13 years must be willing and able to give informed assent
  • An adult (\>18 year of age) parent or guardian must be present at the time of the examination who can give informed consent for children \<18 years to be examined.

You may not qualify if:

  • Individuals for whom no adult parent/guardian is available to provide consent and/or who are unwilling to provide assent/consent for themselves.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Maryland County

Harper, Maryland County, Liberia

Location

Biospecimen

Retention: SAMPLES WITH DNA

Specimens will be obtained from all clinically suspected cases, for confirmatory diagnosis. These include: * skin swabs of suspected yaws lesions * nasal swabs of suspected leprosy cases * skin swabs of Buruli ulcer lesions Samples will be tested using molecular analysis including PCR and sequencing for detection of T. pallidum, M. Ulcerans, M. leprae and other pathogens which can cause similar manifestations. Samples are to be stored (in Liberia, and in London) at -20 degrees in appropriately secured laboratory freezers (CL2 and CL3) for future research projects. This is explained in the information sheet, with a statement included in the consent forms.

MeSH Terms

Conditions

LeprosyBuruli UlcerYawsElephantiasis, Filarial

Condition Hierarchy (Ancestors)

Mycobacterium Infections, NontuberculousMycobacterium InfectionsActinomycetales InfectionsGram-Positive Bacterial InfectionsBacterial InfectionsBacterial Infections and MycosesInfectionsSkin UlcerSkin DiseasesSkin and Connective Tissue DiseasesTreponemal InfectionsSpirochaetales InfectionsGram-Negative Bacterial InfectionsSkin Diseases, BacterialSkin Diseases, InfectiousFilariasisSpirurida InfectionsSecernentea InfectionsNematode InfectionsHelminthiasisParasitic DiseasesMosquito-Borne DiseasesVector Borne DiseasesLymphedemaLymphatic DiseasesHemic and Lymphatic Diseases

Study Officials

  • Rachel L Pullan, PhD

    London School of Hygiene and Tropical Medicine

    PRINCIPAL INVESTIGATOR
  • Karsor Kollie, MSc

    Ministry of Health, Liberia

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
OTHER
Time Perspective
CROSS SECTIONAL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Associate Professor

Study Record Dates

First Submitted

September 19, 2018

First Posted

September 25, 2018

Study Start

June 14, 2018

Primary Completion

October 30, 2018

Study Completion

December 30, 2018

Last Updated

June 10, 2024

Record last verified: 2024-06

Locations